Inhibitive effect of Astragalus on hepatic fibrosis
WANG Dengni1, XU Junquan1, SONG Weifang1, ZHANG Xiaoyang2, WANG Mingliang1, LIANG Yonggang1 (1.Science and Technology Center, Fenyang College of Shanxi Medical University, Fenyang 032200, China; 2.Department of Pathology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China)
Objective: To observe the action of Astragalus on anti-hepatic fibrosis, in order to probe into the mechanism of Astragalus in resisting hepatic fibrosis. Methods: Normal control group, model group and Astragalus treatment group were set in the experiment, model of hepatic fibrosis was induced by subcutaneous injection of carbon tetrachloride (CCl 4). Astra- galus treatment group was given subcutaneous Astragalus when establishing models. Liver tissues were stained with hema - toxylin-erosin to observe liver injury. The degree of liver fibrosis was observed by stained of sirius red of collagen and the content of hydroxyproline in liver tissues. Endotoxin was measured with a limulus amebocyte lysate test kit. Plasma alanine aminotransferase (ALT) was determined with Reitman-Frankel method; the content of malondialdehyde (MDA) in liver tis - sue was determined with TBA method. Results: Astragalus treatment group compared with model group: ①changes in liver damage were relieved, HYP in liver tissue and hepatic fibrosis index (FI) were significantly reduced; ②plasma endotoxin, ALT and liver MDA were reduced to different degrees. Conclusion: Astragalus can alleviate CCl4-induced liver injury, stave happening and developing of hepatic fibrosis; Astragalus can reduce intestinal endotoxemia, which may be one of the mechanisms contributing to the prevention and treatment of Astragalus on liver fibrosis.
【CateGory Index】： R285.5